B of A Securities Downgrades Biohaven to Underperform, Lowers Price Target to $11
Bank of America Securities downgrades Biohaven to Underperform.
B of A Securities analyst Jason Gerberry downgrades Biohaven (NYSE: BHVN ) from Neutral to Underperform and lowers the price target from $12 to $11.